SCHEMBL1368664

SCHEMBL1368664

Cc1nc(Cl)c2c3c(oc2n1)CCCC3

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.37
OPRK1 P41145 1/20 0.35
HTT P42858 3/20 0.34
GLA P06280 1/20 0.34
POLB P06746 1/20 0.34
MAPT P10636 4/20 0.32
ALDH1A1 P00352 3/20 0.32
LMNA P02545 2/20 0.32
L3MBTL1 Q9Y468 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPSR1 Q6W5P4 2/20 0.32
NPC1 O15118 2/20 0.31
RAB9A P51151 2/20 0.31
CYP1A2 P05177 1/20 0.31
HPGD P15428 1/20 0.31
CYP2C19 P33261 1/20 0.31
NSD2 O96028 1/20 0.31
MAPK1 P28482 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4765438 0.77 OPRK1 (0.33) KDM4EOPRK1POLBALDH1A1LMNA
SCHEMBL1367899 0.67 CYP1A2 (0.50) KDM4EHTTMAPTALDH1A1LMNA
SCHEMBL15406756 0.67 MEN1 (0.40) OPRK1POLBALDH1A1LMNAMEN1
SCHEMBL3106221 0.66 MAPK1 (0.44) KDM4EALDH1A1LMNAMEN1KMT2A
SCHEMBL9905748 0.64 KDM4E (0.33) KDM4E
SCHEMBL1368324 0.64 KMT2A (0.56) KDM4EHTTMAPTALDH1A1LMNA
SCHEMBL12560223 0.62 ALDH1A1 (0.39) KDM4EHTTGLAPOLBMAPT
SCHEMBL1069076 0.62 KDM4E (0.41) KDM4EHTTMEN1KMT2ANPSR1
SCHEMBL29881989 0.61 KMT2A (0.55) KDM4EHTTPOLBMAPTALDH1A1
SCHEMBL13424563 0.61 ACHE (0.44) KDM4EMAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11091500-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2021-08-17 US disclosed
US-11091500-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2021-08-17 US disclosed
US-10676483-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2020-06-09 US disclosed
US-10676483-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2020-06-09 US disclosed
EP-2310014-B1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF UNIV HOLY GHOST DUQUESNE (US) 2020-03-18 EP disclosed
EP-2310014-B1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF UNIV HOLY GHOST DUQUESNE (US) 2020-03-18 EP disclosed
US-20200017521-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2020-01-16 US disclosed
US-20200017521-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2020-01-16 US disclosed
US-10464944-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2019-11-05 US disclosed
US-10464944-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2019-11-05 US disclosed
US-20110288108-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF GANGJEE ALEEM (US) 2011-11-24 US disclosed
US-20110288108-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF GANGJEE ALEEM (US) 2011-11-24 US disclosed
US-20110288108-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF GANGJEE ALEEM (US) 2011-11-24 US disclosed
US-7982035-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2011-07-19 US disclosed
US-7982035-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2011-07-19 US disclosed
US-7982035-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2011-07-19 US disclosed
WO-2010006032-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) 2010-01-14 WO disclosed
US-20090082374-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2009-03-26 US disclosed
US-20090082374-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2009-03-26 US disclosed
US-20090082374-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF DUQUESNE UNIVERSITY OF THE HOLY SPIRIT 2009-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082374-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF ABCG2, ABCC1, ABCB1 KDM4E 3957/4885OPRK1 3263/4885HTT 2780/4885
US-20200017521-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF PLK1, AURKC, TOP1 KDM4E 3049/4885OPRK1 4321/4885HTT 1939/4885
US-20110288108-A1 TRICYCLIC COMPOUNDS HAVING ANTIMITOTIC AND/OR ANTITUMOR ACTIVITY AND METHODS OF USE THEREOF ABCG2, ABCC1, ABCB1 KDM4E 3957/4885OPRK1 3263/4885HTT 2780/4885
US-10676483-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof PLK1, AURKC, TOP1 KDM4E 3049/4885OPRK1 4321/4885HTT 1939/4885
US-11091500-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof ABCC1, ABCB1, ABCG2 KDM4E 4030/4885OPRK1 3497/4885HTT 2514/4885
US-10464944-B2 Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof ABCC1, ABCG2, TP53 KDM4E 4107/4885OPRK1 3470/4885HTT 2053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.